UPDATED Aug 05, 2022
Companies which may present a buying opportunity after a dip in share price.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
CHRSCoherus BioSciences | US$11.83 | 39.7% | -9.1% | US$915.9m | US$18.50 | PS3.3x | E73.2% | n/a | ||
CTICCTI BioPharma | US$7.43 | 13.6% | 165.4% | US$809.6m | US$9.79 | PS352.8x | E67.4% | n/a | ||
FOLDAmicus Therapeutics | US$12.18 | 22.3% | 16.0% | US$3.4b | US$14.50 | PS10.6x | E69.5% | n/a | ||
OPTNOptiNose | US$3.68 | 1.7% | 37.3% | US$304.3m | US$7.50 | PS3.9x | E67.6% | n/a | ||
ADMAADMA Biologics | US$2.14 | 0% | 35.4% | US$420.2m | US$4.50 | PS4.5x | E67.3% | n/a | ||
ICPTIntercept Pharmaceuticals | US$16.42 | 28.7% | -1.2% | US$489.3m | US$26.47 | PS1.3x | E49.7% | n/a | ||
AVIRAtea Pharmaceuticals | US$8.79 | 7.2% | -71.8% | US$731.8m | US$10.25 | PE15.1x | E45.3% | n/a | ||
CLVRClever Leaves Holdings | US$1.02 | 10.9% | -90.4% | US$40.9m | US$3.30 | PS2.4x | E69.6% | n/a | ||
AVEOAVEO Pharmaceuticals | US$7.78 | 8.7% | 30.8% | US$268.2m | US$16.25 | PS3.4x | E73.0% | n/a | ||
BCRXBioCryst Pharmaceuticals | US$14.05 | 27.5% | -20.2% | US$2.6b | US$16.20 | PS12.8x | E68.9% | n/a | ||
BHVNBiohaven Pharmaceutical Holding | US$146.98 | 0.7% | 18.0% | US$10.4b | US$153.56 | PS12.1x | E70.3% | n/a | ||
CASICASI Pharmaceuticals | US$2.50 | 1.2% | -79.0% | US$34.0m | US$37.00 | PS1x | E73.0% | n/a | ||
VBIVVBI Vaccines | US$1.06 | 24.6% | -65.6% | US$273.8m | US$6.67 | PS602.3x | E70.2% | n/a | ||
QUREuniQure | US$25.54 | 0.7% | -16.3% | US$1.2b | US$51.47 | PE3.7x | E21.9% | n/a | ||
FBIOFortress Biotech | US$1.21 | 40.6% | -63.8% | US$130.0m | US$6.08 | PS1.6x | E61.3% | n/a | ||
OPNTOpiant Pharmaceuticals | US$11.84 | 15.3% | -26.7% | US$60.2m | US$40.25 | PS1.3x | E75.5% | n/a | ||
CLNNClene | US$3.64 | 8.7% | -60.2% | US$230.3m | US$14.71 | PE13.8x | E82.5% | n/a | ||
EOLSEvolus | US$9.40 | -23.8% | -18.7% | US$527.3m | US$16.38 | PS4x | E69.4% | n/a | ||
AUPHAurinia Pharmaceuticals | US$8.37 | 2.3% | -42.0% | US$1.2b | US$23.31 | PS13.5x | E70.8% | n/a | ||
MNKDMannKind | US$4.33 | 25.5% | 7.2% | US$1.1b | US$5.60 | PS15.6x | E68.2% | n/a | ||
RDHLRedHill Biopharma | US$0.96 | 10.3% | -86.5% | US$56.0m | US$7.75 | PE-0.6x | E67.8% | n/a | ||
CORTCorcept Therapeutics | US$28.70 | 0.1% | 31.5% | US$3.0b | US$32.17 | PE27x | E30.5% | n/a | ||
HZNPHorizon Therapeutics | US$69.60 | -16.1% | -34.3% | US$16.0b | US$105.71 | PE21x | E25.7% | n/a | ||
SLGLSol-Gel Technologies | US$5.88 | 4.8% | -41.4% | US$136.0m | US$17.67 | PE14.2x | E50.7% | n/a |